What are the functions and effects of selinesol tablets?

Selinexor-based therapies have been approved for the treatment of relapsed/refractory multiple myeloma (RRMM) based on a clinical trial program that includes multiple combination treatment options. Nisol and dexamethasone are approved for patients with late relapse who are refractory to penta-drug therapy, and seliniso, bortezomib and dexamethasone are approved for patients who have received ≥ 1 prior therapy. Selinisol is also being studied in several other mid-stage and late-stage clinical trials in multiple high-need unmet cancer indications, including endometrial cancer and myelofibrosis.

Selinisol belongs to a class of drugs called Selective Inhibitor of Nuclear Export (SINE). By inhibiting the activity of protein XPO1, it prevents the normal transport and localization of key proteins in cancer cells, thereby interfering with the survival and proliferation of cancer cells. This mechanism helps slow tumor growth and may lead to cancer cell death. This treatment regimen, in which selinesol tablets are used in combination with other drugs, may improve treatment response rates and survival in patients with multiple myeloma.

Seleniso is a prescription drug and must be used under the guidance of a professional doctor. Before starting treatment, the doctor will comprehensively evaluate the patient's health and tailor a personalized treatment plan based on the patient's specific situation. During treatment, patients should pay close attention to their body's reactions and report any discomfort or abnormal symptoms to their doctor immediately. Doctors will flexibly adjust drug dosages, optimize treatment plans or provide corresponding supportive treatment measures based on patients' real-time feedback to ensure the safety and effectiveness of treatment.